

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office  List of Documents Cited by Applicant			 Attorney Docket No. 421/60/18/2/2		Serial No. 10/796,657		
			Applicant(s): Dykstra et al.				
			Filing Date: March 9, 2004		Group 1633		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No	
<i>MA</i>	1.	179856	7/18/1995	JP	Canon Kk	<input checked="" type="checkbox"/> (abstract)	
<i>MA</i>	2.	02/36588	5/10/2002	PCT	U.S. Army		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<i>MA</i>	3.	Del Poeta et al., <i>In Vitro Antifungal Activities of a Series of Dication-Substituted Carbazoles, Furans, and Benzimidazoles</i> , <i>Antimicrobial Agents and Chemotherapy</i> 42, No. 10:2503-2510 (October 1998).					
<i>MA</i>	4.	International Search Report for PCT/US02/00787 (September 12, 2002).					

EXAMINER Neesha D DATE CONSIDERED 12-13-2005

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



10-1449 U.S. Department of Commerce  
Patent and Trademark Office

## List of Documents Cited by Applicant

Application No.:	10/796,657
Filing Date:	March 9, 2004
First Named Inventor:	Dykstra et al.
Group:	1624
Examiner:	Nyeemah Grazier
Attorney Docket No.:	421/60/18/2/2

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
NG	1	FR 1,464,999	12/31/1965	Harnisch et al.		
NG	2	GB 1,084,175	9/20/1967	CIBA Limited		
NG	3	BE 641,607	6/22/1964	CIBA Societe Anonyme		
NG	4	WO 01/03685 A2	1/18/2001	Boykin et al.		
NG	5	WO 01/46175 A1	6/28/2001	Wilson et al.		

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
NG	6	European Search Report for corresponding European app. no. 02705743.9 dated July 15, 2005.	
NG	7	BOYKIN ET AL., "Anti-Pneumocystis Activity of Bis-Amidoximes and Bis-O-Alkylamidoximes Prodrugs", <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , 6 (24): 3017-3020, 1996.	
NG	8	WANG ET AL., "Specific Molecular Recognition of Mixed Nucleic Acid Sequences: An Aromatic Dication that Binds in the DNA minor Groove as a Dimer", <u>PNAS</u> , 97 (1): 12-16, January 4, 2000.	
NG	9	TRALIC-KULENOVIC ET AL., "Synthesis and Absorption Spectral Properties of Substituted Phenylfurylbenzothiazoles and their Vinyllogues", <u>Monatshefte fur Chemie</u> , 125: 209-215, 1994.	

12-13-2005

<i>MG</i>	10	GELUS ET AL., "Inhibition of HIV-1 Tat-TAR Interaction by Diphenylfuran Derivatives: Effects of the Terminal Basic Side Chains", <u>Bioorganic &amp; Medicinal Chemistry</u> , 7: 1089-1096, 1999.	
<i>MG</i>	11	ZAPP ET AL., "Modulation of the Rev-RRE Interaction by Aromatic Heterocyclic Compounds", <u>Bioorganic &amp; Medicinal Chemistry</u> , 5 (6): 1149-1155, 1997.	
<i>MG</i>	12	RATMEYER ET AL., "Inhibition of HIV-1 Rev-RRE Interaction by Diphenylfuran Derivatives", <u>Biochemistry</u> , 35: 13689-13696, 1996.	
<i>MG</i>	13	DE CLEREQ ET AL., "Diaryl Amidine Derivatives as Oncornaviral DNA Polymerase Inhibitors", <u>J. Med. Chem.</u> , 23: 787-795, 1980	
<i>MG</i>	14	WANG ET AL., "Evaluation of the Influence of Compound Structure on Stacked-Dimer Formation in the DNA Minor Groove", <u>Biochemistry</u> , 40: 2511-2521, 2001.	

EXAMINER Nicole G. DATE CONSIDERED 12.13.2005

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.